My research program seeks to employ systems biology and functional genomics approaches to alleviate the burden of renal cell carcinoma (RCC). The majority (~75%) of RCCs are clear cell renal cell carcinomas (ccRCC), characterized by their marked heterogeneity in terms of clinical outcomes. Most patients (75-80%) present with apparent localized disease, for whom radical/partial nephrectomy or tumor ablation is standard of care. Overall, a third of patients subsequently relapse. Even amongst patients with metastatic disease, survival can vary tremendously, from just a few months to several years. This heterogeneity poses significant challenges to the delivery of precision care, including accurately identifying high-risk patients post-surgery, and selecting the most effective treatments.
The overall objectives of this program are to identify robust genomic markers of outcome and novel effective therapeutic strategies for precision medicine for RCC. We will harness the power of computational medicine and use a variety of genomic techniques to map interactions between genomic variations of tumor cells and patient/host factors (particularly the tumor microenvironment) to open new avenues for personalized healthcare delivery to RCC patients.